c-JUN N-TERMINAL KINASES/c-JUN AND p38 PATHWAYS COOPERATE IN CERAMIDE-INDUCED NEURONAL APOPTOSIS

S. WILLAIME-MORAWEK, a,b K. BRAMI-CHERRIER, a,b J. MARIANI, b J. CABOCHE a AND B. BRUGG a,b*

aLaboratoire Signalisation Neurionale et Régulation Génique (UMR 7102), Case 12, 9 quai Saint Bernard, 75005 Paris, France
bLaboratoire Développement et Vieillissement du Système Nerveux (UMR 7102), Case 14, 9 quai Saint Bernard, 75005 Paris, France

Abstract—Understanding the regulation of the apoptotic program in neurons by intracellular pathways is currently a subject of great interest. Recent results suggest that c-Jun N-terminal kinases (JNK), mitogen-activated protein kinases and the transcription factor c-Jun are important regulators of this cell death program in post-mitotic neurons following survival-factor withdrawal. Our study demonstrates that ceramide levels increase upon survival-factor withdrawal in primary cultured cortical neurons. Furthermore, survival-factor withdrawal or addition of exogenous c2-ceramide induces JNK pathway activation in these cells. Western blot analyses of JNK and c-Jun using phospho-specific antibodies reveal that JNK and subsequent c-Jun phosphorylation occur hours before the initiation of apoptosis, reflected morphologically by neurite retraction and fragmentation, cell-body shrinkage and chromatin fragmentation. Immunochemistry using the same antibodies shows that phospho-JNK are localized in the neurites of control neurons and translocate to the nucleus where phospho-c-Jun concurrently appears upon ceramide-induced apoptosis. To determine if ceramide-induced c-Jun activation is responsible for the induction of the apoptotic program, we performed transient transfections of a dominant negative c-Jun-expressing neurons with the pharmacological inhibitor of p38 kinase, SB203580, completely blocked neuronal death. Thus our data show that p38 and JNK/c-Jun pathways cooperate to induce neuronal apoptosis. © 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.

Key words: primary cultures, SAPK, serum withdrawal, neuronal death.

Many recent studies have sought to identify the key components of the cell-death machinery in neurons and to understand how the cell-death program is regulated by intracellular signaling pathways activated by death factors, binding to specific cell-surface receptors. Recent results suggest that mitogen-activated protein kinase (MAP), c-Jun N-terminal kinases (JNK) and p38 are important regulators of the cell death program in post-mitotic neurons following survival-factor withdrawal (Mielke and Herdegen, 2000). Experiments with sympathetic neurons cultured in vitro, as well as with cerebellar granule neurons and differentiated pheochromocytoma 12 (PC12) cells, have demonstrated that JNK/c-Jun and p38 signaling can promote apoptosis following survival-factor withdrawal. Overexpression of dominant negative components of the JNK or the p38 pathway reverses apoptosis induced by trophic-factor withdrawal in PC12 cells (Xia et al., 1995).

One major target of the JNK pathway is the transcription factor c-Jun, which is regulated at both transcriptional and post-transcriptional levels by activated JNK (Davis, 2000). C-Jun may play a role in a wide variety of phenomena including survival, differentiation, and neuronal regeneration (Herdegen et al., 1997). Recent evidence, wherein blocking c-Jun function has protected neurons from apoptosis, both in vitro (Estus et al., 1994; Ham et al., 1995) and in vivo (Behrens et al., 1999; Crocker et al., 2001), has specifically implicated c-Jun in apoptosis.

Recent studies in cultured cortical neurons have demonstrated that increased ceramide levels, a second messenger generated intracellularly by the sphingomyelinase-mediated cleavage of sphingomyelin, activate MAP kinase JNK and p38, subsequent to induction of apoptosis (Willaime et al., 2001). Ceramide generation has been reported as a mechanism for induction of apoptosis in response to a variety of lethal agents such as tumor necrosis factor, Fas-ligand, ionizing radiation, ultraviolet-C, heat shock, oxidative stress and growth factor withdrawal in non-neuronal cells (Mathias et al., 1998). Its implication in apoptotic processes is strongly supported by experiments on lymphoblasts from Niemann-Pick patients expressing inactive sphingomyelinase or cultured fibroblasts from acid sphingomyelinase knockout mice. In both situations cells failed to respond to ionizing radiation-induced apoptosis (Santana et al., 1996; Lozano et al., 2001). These defects, as well as ceramide production, can be reversed when acid sphingomyelinase activity is restored, suggesting that ceramide is a central molecule in the apoptotic machinery.

Previous studies using in vitro models of neuronal death also implicate ceramide in the apoptotic process. Firstly, sphingomyelinase activity is strongly in-

0306-4522/03/$30.00 © 2003 IBRO. Published by Elsevier Science Ltd. All rights reserved.
doi:10.1016/S0306-4522(02)00996-X
creased during developmental neuronal death in rat brain (Spence and Burgess, 1978). Secondly, increased ceramide levels are observed during apoptosis induced by growth factor withdrawal in PC12 cells (Lambeng et al., 1999) and after lethal ischemia in the gerbil hippocampus (Nakane et al., 2000). Furthermore, apoptosis can be induced by exogenous ceramide treatment of PC12 cells (France-Lanord et al., 1997; Hartfield et al., 1997), mesencephalic (Brugg et al., 1996), hippocampal (Mitoma et al., 1998) or cortical neurons (Willaime et al., 2001).

The objective of this study was to evaluate the role of the signaling cascade downstream ceramide after survival-factor withdrawal in cortical neurons. Using a dominant negative transfection approach in combination with a pharmacological inhibitor, we analyze herein the contribution of JNK/c-Jun and p38 pathways in ceramide-induced neuronal cell death.

EXPERIMENTAL PROCEDURES

Materials

C2-ceramide (N-acetylsphingosine, Biomol Research Laboratory, Plymouth Meeting, PA, USA) was prepared as a 25 mM stock in ethanol and incubated in the culture media as described. The specificity of C2-ceramide was evaluated by comparing its effects with those of C2-dihydro-ceramide (Biomol Research Laboratory, Plymouth Meeting, PA, USA), an analog lacking the 4–5 trans double bond in the sphingosine moiety of C2-ceramide, which has been shown to be incapable of activating the sphingomyelin pathway in lymphocytes (Bielawska et al., 1993; Obeid et al., 1993) and neurons (Brugg et al., 1996).

Primary cultures of mouse cortex

Embryos were removed at day 14 from timed-pregnant Swiss mice (Janvier, Le Genest-St-Isle, France). The cortex was dissected, mechanically dissociated and plated on polyethyleneimine (1 mg/ml) coated culture wells, in Eagle’s basal medium (Eurobio, Les Ulis, France), supplemented with 5% horse serum (HS; Eurobio), 2.5% fetal calf serum (FCS; Eurobio, Les Ulis, France), supplemented with 5% horse serum (HS; Eurobio), and 2.5% fetal calf serum (FCS; Eurobio), at a density of 7.105 cells/cm2. After 2 days in culture the media was replaced by N5 medium (Kawamoto and Barrett, 1986) with 180 mg/l glucose and changed daily; FCS content was reduced to 1%; with N5 medium (Kawamoto and Barrett, 1986) with 180 mg/l glucose and changed daily; FCS content was reduced to 1%; Ara-C (cytosine arabinoside, 3 μM, Sigma, Saint Louis, MO, USA) was added to prevent astrocyte proliferation (our cultures were at least 95% neuronal after this treatment), and MK-801 (1 μM, Research Biochemicals International, Natick, MA, USA) to prevent excitotoxicity (Krusel et al., 1990; Brugg et al., 1996). All experiments conformed to French and international guidelines on the ethical use of animals. We minimized the number of animals used and their suffering.

Serum deprivation

Cells were deprived in serum after 5 days of in vitro culture. Culture medium N5 5% HS and 1% FCS, MK-801, Ara-C was replaced by N5 without serum but with MK-801, after washing cells three times in this last medium.

Lipid extraction and ceramide quantization

Cells were washed with phosphate-buffered saline (PBS) and scraped. After spinning 5 min at 4 °C, cell pellets were resuspended in water and homogenized by brief sonication. Aliquots were saved for protein quantification. Lipids were extracted and ceramide was quantitated using Escherichia coli diacylglycerol kinase and 32P-γ-ATP (NEN, Boston, MA, USA) according to previously published procedures (Van Veldhoven et al., 1992). Lipids were then resolved by thin-layer chromatography; radioactivity associated with ceramides was scraped and quantitated by liquid-scintillation spectrometry.

Ceramide treatment

Embryonic cortical neurons cultivated in 5% HS and 1% FCS, optimal conditions for their maturation and differentiation, were insensitive to C2-ceramide treatment. That is why we reduced serum content to 1% HS, 24 h before any ceramide treatment (Brugg et al., 1996). Thus, the effects seen were not due to partial serum deprivation but rather to specific treatment, since control cells were in the same serum conditions during the same time as the treated cells. The culture conditions (concentration and time course) under which C2-ceramide provokes cell death were determined by a cell-viability test.

Cell viability

Cell viability was determined by counting viable cells after a 10- min treatment with bisbenzimide (Hoechst; 0.8 μg/ml), Triton X-100 (0.005%) or with the 3(4,5-dimethylthiazol-2-yl)-2,5-diphenylnitrophenazolium bromide (MTT) assay (the conversion of the yellow tetrazolium salt, MTT, to the purple formazan dye depends upon the mitochondrial activity; Slater et al., 1963; Altman, 1976). The MTT assay was performed on neurons in N5 medium 1% HS, with MTT (0.5 mg/ml) for 2 h in a humidified atmosphere at 37 °C, 5% CO2. The purple formazan salt was solubilized in 100 μl of a solution containing 0.1 M HCl in isopropanol. The spectrophotometric absorbency of the samples was determined at a 560 nm wavelength.

Transfections

Transient transfection of primary cortical cultures was performed with LipofectAMINE 2000 (Invitrogen, Groningen, The Netherlands) as recommended by the manufacturer’s protocol. Cells were transfected with 1 μg of enhanced green fluorescent protein (EGFP-N3; Clontech, Cambridge, UK) alone or in the presence of 5 μg of the dominant negative c-Jun (DN-c-Jun; Ham et al., 1995) after 6 h, the cultures were rinsed with fresh medium. Transfection efficacy was 3–5% of the cells. After treatments, the cells were fixed as described below. Immunocytochemical analysis of DN-c-Jun expression was performed using a mouse monoclonal anti-flag M2 antibody (Sigma), and an anti-mouse Cy3 conjugated antibody (1:1000, Amersham, UK) with the protocol described below for P-JNK and P-c-Jun immunodetection.

Immunocytochemistry

After C2-ceramide treatment, cells were fixed in the super cells cultured dishes with PBS containing 4% paraformaldehyde for 20 min and then incubated with methanol/acetonitrile solution (50/50) for 10 min at 4 °C. Then, after washing three times with PBS, plates were treated with blocking buffer containing FCS 10%, bovine serum albumin (BSA) 1% in PBS for 2 h. Polyclonal antibodies raised against double phosphorylated SAPK/JNK (Thr183-Tyr185) (P-JNK) (P-JNK, 1:500, New England Biolabs, Ozyme, France) or Phospho-c-Jun (Ser63-c-Jun) (P-c-Jun, 1:500, New England Biolabs) were incubated overnight at 4 °C in PBS containing 1% BSA, 0.05% Tween 20. Plates were rinsed in PBS and incubated with an anti-rabbit fluorescein isothiocyanate-conjugated antibody (1:750, Amersham, UK) for 2 h. After counterstaining with propidium iodide, cells were mounted under coverslips using vectashield (Vector Abscis, France).
Subcellular fractionation

Neurons were cultured in six-well plates, placed on ice, and lysed in buffer containing Tris-EDTA, 1 mM, NaCl 50 mM, NaPPi 30 mM, Triton X-100 10%, NaF 1 M and a mix of protease and phosphatase inhibitors (100 μM Na3VO4, 1 mM dithiothreitol, 100 mM okadaic acid, 2.5 μg/ml aprotinin, 2.5 μg/ml pepstatin, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM benzamidine, 0.5 μg/ml leupeptin). Cells were homogenized with a dounce A and then centrifugated (for 10 min at 1000×g at 4 °C). The supernatant corresponding to the cytosolic fraction was removed. The pellets corresponding to the nuclear fraction were washed twice with lysis buffer. Protein extracts (10 μg from each fraction) were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) before electrotransfer. Blots were blocked with 5% nonfat milk and incubated with rabbit polyclonal antisera raised against JNK (1:1000, New England Biolabs) or Egr-1 (1:500; Santa Cruz, Santa Cruz, CA, USA) overnight at 4 °C. After rinsing, the blots were incubated with goat horseradish peroxidase-conjugated antibody (1:2500) for 2 h at room temperature before exposure to the ECL kit (Amersham).

Western blot analysis

Cultured neurons were lysed in solubilization buffer (10 mM Tris–HCl, 50 mM NaCl, 1% Triton X-100, 30 mM Na4P2O7, 50 mM NaF, 5 μM ZnCl2, 100 μM Na3VO4, 1 mM dithiothreitol, 5 mM okadaic acid, 2.5 μg/ml aprotinin, 3.6 μg/ml pepstatin, 0.5 μM phenylmethylsulfonyl fluoride, 0.5 mM benzamidine, 5.3 μM leupeptin) at 4 °C. Insoluble material was removed by centrifugation (10,000×g for 30 min at 4 °C) and samples were stored at −80 °C. The proteins were dosed with the DC protein assay kit (Bio-Rad, Hercules, CA, USA). Cell extracts containing aliquots (usually 5 μg protein) were boiled for 5 min in sample loading buffer. After a 10% SDS-PAGE, proteins were transferred to a polyvinylidene difluoride membrane (ICN Biochemicals, Costa Mesa, CA, USA). Non-specific sites were blocked with 5% skimmed dried milk for 2 h. Blots were incubated overnight at 4 °C with primary polyclonal antibodies raised against human phosphorylated SAPK/JNK (Thr183/Tyr185-JNK; P-JNK, 1:1000, New England Biolabs) or P-c-Jun (Ser63-Jun: 1:1000, New England Biolabs) in 5% BSA. They were then incubated with horseradish peroxidase-conjugated secondary rabbit polyclonal antibody (1:2500) in 5% skimmed dried milk for 1 h. The revelation was processed with the Densylab software (Microvision Instruments, Evry, France).

RESULTS

Serum withdrawal-induced neuronal apoptosis increases ceramide levels in cortical neurons

Cortical neurons were deprived of serum after a 5-day maturation period in vitro and assayed for cell viability at various time points after treatment using the MTT metabolism assay (Fig. 1A). No significant loss of viability was detected during the first 6 h of treatment; however, after this lag phase the neurons degenerated progressively. After 24 and 42 h, 52% and 37% of the cells survived in the culture respectively (Fig. 1A).

We measured ceramide levels, a stress and apoptotic lipid second messenger, during serum withdrawal in cultured cortical neurons. There was a biphasic increase in ceramide levels: a rapid two-fold induction after 0.5 h that then decreased and another 2.5-fold induction after a 16-h serum withdrawal, compared with the control value (Fig. 1B). Thus, serum withdrawal-induced apoptosis in cortical neurons induces ceramide levels increase in two distinct waves.

Cortical neurons were treated after a 5-day maturation period in vitro with C2-ceramide and assayed for cell viability at various times after treatment using the MTT metabolism assay (Fig. 1C). After a 24-h treatment, survival was inversely correlated with C2-ceramide concentration in the range between 10 and 75 μM (Willaime et al., 2001). At the concentration we used (40 μM) no significant loss of viability was detectable during the first 12 h of treatment; after that the neurons degenerated progressively. After 24 and 48 h, 50% and 10% of the cells survived in the culture respectively (Fig. 1C).

Serum withdrawal and ceramide use a common apoptotic pathway including JNK phosphorylation

We have previously described JNK activation in ceramide-induced apoptosis (Willaime et al., 2001) and here we have analyzed JNK activation during serum withdrawal in cortical neurons by Western blot. Three different genes (JNK1, JNK2, JNK3) encode for the JNK proteins, each in giving rise to alternatively spliced isoforms (Gupta et al., 1996) whose in vitro translation produces two major proteins of 54 and 46 kD. JNKs are activated by dual phosphorylation on residues Thr183 and Tyr185 (P-p54 and P-p46). Using an antibody specifically directed against active JNKs, we found that serum withdrawal gradually increased P-p54 and P-p46 levels throughout the 24 h of treatment (Fig. 2A, upper panel). Using the same antibody, we found that C2-ceramide (40 μM) increased P-p54 and P-p46 levels (Fig. 2B, upper panel), as previously described (Willaime et al., 2001). These increases resulted from phosphorylation, as the total JNK levels did not increase significantly during treatment (Fig. 2A and 2B, lower panels). P-p46 level increased more slowly with serum withdrawal than ceramide treatment, and reached 250% of the control values after a 24-h treatment under both conditions (Fig. 2C). Thus serum withdrawal and ceramide treatment induced a strong activation of JNKs.

C2-ceramide induces P-JNK nuclear translocation and subsequent c-Jun phosphorylation during apoptosis of cortical neurons

As JNKs have a wide variety of potential phosphorylation substrates it is important to analyze the localization of P-JNK within the cell to understand its possible effects upon nuclear transcription factors. Immunocyto-
chemical detection of the phosphorylated and thereby active form of JNKs (P-JNKs), was used and kinetics of JNK activation were analyzed in this model system by immunofluorescence (Fig. 3A). A low basal level of P-JNK immunoreactivity was found in control cells that corresponded, nevertheless, to an exclusive neuritic localization. After 8 h of C₂-ceramide (40 μM) treatment and thereafter, P-JNK immunoreactivity showed a distinct localization in a vast majority of neurons, confirmed by confocal microscopy analysis (Fig. 3A, insert). To confirm this biochemically, we fractionated cortical extracts into the nucleus and the cytoplasm. As a control of our fractionation procedure, Egr-1 immunoblotting was performed and showed an immunoreactive band at 57 kD, the expected molecular weight for Egr-1, in the nuclear extract almost exclusively. From these fractions, we then analyzed the distribution of JNK by immunoblotting. This shows a strong increase in nuclear JNK p46 isoform after ceramide treatment (Fig. 3B), corresponding to the nuclear labeling of P-JNK found by immunocytochemistry (Fig. 3A), with no translocation of JNK p54 isoform. This result together with immunocytochemical analyses of P-JNKs strongly support that p46 is the major JNK isoform (see Fig. 2B) phosphorylated and translocated upon ceramide treatment. Together these data show that JNKs are activated and translocated into the nucleus during ceramide treatment.

Within the nucleus, activated JNKs are known to control the phosphorylation state of c-Jun as well as its transcriptional control (Angel et al., 1988). By Western blot using an antibody specific for the phosphorylated form of c-Jun (P-c-Jun), we found that C₂-ceramide increased phosphorylation of c-Jun at 10 and 16 h of ceramide treatment (Fig. 4A), compared with loading control with the total JNKs that did not change during ceramide treatment.

Next, we examined c-Jun phosphorylation by immunocytochemistry with the same antibody (Fig. 4B). In contrast to control neurons (t₀), where we failed to detect any P-c-Jun-immunoreactivity (green), P-c-Jun-immunoreactivity appeared after 8 h of C₂-ceramide (40 μM) treatment and strong levels persisted well after 16 h of treatment. Thus, c-Jun phosphorylation appears with JNK activation and translocation.

**Overexpression of dominant negative c-Jun blocks ceramide-induced apoptosis in primary cortical neurons**

To address the role of c-Jun activation in ceramide-induced neuronal apoptosis, we overexpressed a dominant negative form of c-Jun (DNC-Jun) in primary cortical neurons. We used a construct corresponding to a deletion of...
the first 169 amino acids, the region containing the transactivation domain, which contains the phosphorylation target sites of activated JNK (Ham et al., 1995). Neurons were transfected with GFP alone or in combination with DNc-Jun. GFP expression allowed for visualization of the cytoarchitecture, including neuritic extension of transfected neurons and cell body (analyzed after 24 h of c2-ceramide treatment) in transfected neurons. Immunocytochemical detection of DNc-Jun showed its nuclear localization, as well as coexpression with GFP in double-transfected neurons (Fig. 5H). In control conditions, neurons transfected with GFP alone (Fig. 5A, B) or in combination with DNc-

Fig. 2. Serum withdrawal (A) and c2-ceramide (B) induce an increase of JNK phosphorylation in cultured cortical neurons. Immunoblot analysis of P-JNKs (P-p54 and P-p46, upper panels) and total JNKs (total p54 and total p46, lower panels) in extracts of treated cortical neurons. (C) Quantification of P-p46 immunoreactivity in Western blot analyses during serum withdrawal or ceramide treatment. P-p46 signals were normalized to the corresponding total p46 signal. Data represent mean ± S.E.M., n=4 independent experiments. *P<0.05 compared with the control value, according to the one-way ANOVA followed by Dunnett’s post hoc test.
Jun (Fig. 5G–I) showed very long neuritic extensions and normal nuclei. After 24 h of c2-ceramide (40 μM) treatment, 48.7% of neurons transfected with GFP alone are alive whereas the others exhibited a strong retraction and fragmentation of neurites (Fig. 5C) and nuclear fragmentation (Fig. 5D), quantified in Table 1. In contrast, 77.3% of neurons coexpressing GFP and DNc-Jun and treated for 24 h with ceramide were alive (Fig. 5E, F, Table 1), thus demonstrating that activation of c-Jun plays an important role in ceramide-induced neuronal apoptosis.

Treatment of DNc-Jun-expressing neurons with p38 inhibitor completely protects cortical neurons against ceramide-induced apoptosis

We previously described that SB203580, a specific inhibitor of p38 pathway, also partially protects against ceram-
ide-induced apoptosis (Willaime et al., 2001) in exactly the same conditions as in this new study (Table 1). Here we show that treatment of DNc-Jun-expressing neurons with SB203580 completely protects cortical neurons against ceramide (40 µM)-induced apoptosis: neuronal survival is 96.9% of the control with double treatment, versus 77.3% and 76.0% with DNc-Jun and SB203580 respectively (Table 1).

**DISCUSSION**

Ceramide generation has been reported as a mechanism for the induction of apoptosis in response to different stress stimuli in a variety of non-neuronal cells types. The present study demonstrates that the second-messenger ceramide increases upon survival-factor withdrawal in primary cortical neurons. Serum deprivation increased endogenous ceramide levels in a two-peak manner: the first peak occurred very rapidly within the first hour and the second peak at 16 h after the apoptotic process had already been engaged. These data, together with the previous findings which demonstrate that a 6-h pulse of c2-ceramide treatment is sufficient to commit neurons to die (Hunot et al., 1997), suggest that the first ceramide peak could be responsible for apoptosis induction. This rapid and transient increase of ceramide may reflect an activation of sphingomyelinases, as seen after stimulation of non-neuronal cells with TNF-α, II-1β and Fas-ligand (for review see Kronke, 1997). The mechanism of receptor mediated sphingomyelinase activation after survival-factor withdrawal, however, remains unidentified.

---

**Fig. 4.** (A) Immunoblot analysis of P-c-Jun (upper panel) in extracts of ceramide-treated cortical neurons and loading control with total JNKs (total p54 and total p46, lower panel). (B) C2-ceramide induces an increase of P-c-Jun in the nuclei of cultured cortical neurons. Neurons immunostained for P-c-Jun (green) and nuclear labeled by propidium iodide in cortical cultures. Neurons control (t0) or treated with c2-ceramide (40 µM) during indicated times. White arrows: normal nuclei; arrowheads: condensed and fragmented nuclei. Scale bar=20 µM.
Fig. 5.
The second ceramide peak could reflect an increase in ceramide synthase activity, since it has been reported that fumonisins B1, a ceramide synthase inhibitor, can decrease this second peak (Jaffrezou et al., 1998). This might reveal a cellular degeneration process since this late ceramide level increase is also observed under necrotic conditions (Bose et al., 1995; Jaffrezou et al., 1998). The implication of the rapid ceramide peak in apoptosis induction is further supported by the finding that serum withdrawal or c2-ceramide treatment induces an almost identical time course of JNK phosphorylation (Fig. 2). Ceramide generation and JNK activation could also be correlated in vivo in animal models of ischemia, as data show that ceramide levels increase (Nakane et al., 2000) and JNK1 has been shown to activate and translocate to the nuclei (Mizukami et al., 1997).

To further evaluate JNK activation in neuronal apoptosis involving ceramide we have investigated JNK activation by immunocytochemistry. To our knowledge this is the first documentation showing that ceramide may induce nuclear translocation of JNK in neurons. This event coincides with the increase in JNK phosphorylation (Fig. 2) after 8 h of ceramide treatment. JNK activation and nuclear translocation in neurons have been reported in vivo under different pathological conditions. Nuclear localization of JNK has been detected in degenerating neurons of Alzheimer patients (Zhu et al., 2001) and in cerebellar granule neurons (Coffey et al., 2000, 2002). JNK1 and JNK3 translocation from the cytosol to the nucleus in neurons can also be observed in experimental models of hypoxia (Zhang et al., 1998) and ischemia (Mizukami et al., 1997) respectively.

The mechanism by which ceramide activates the JNK pathway in neurons, however, has yet to be identified. Several intermediate kinases described in other cellular systems may be involved in this process in neurons, including the small G-protein Rac1 (Brenner et al., 1997), the MAP kinase TGFβ-activating kinase 1 (Schirakabe et al., 1997), the MAP 3 kinase 1 (Takekawa et al., 1997) or the apoptosis signal-regulated kinase 1 (Chen et al., 1999). Further investigations will help to determine how ceramide and serum withdrawal induce the JNK pathway in neurons.

JNK activation, and its nuclear translocation, has been associated with transcriptional events that occur early in the apoptotic process (Ham et al., 2000). Consistent with this, nuclear localization of JNK has been observed in experimental models of hypoxia (Zhang et al., 1998) and ischemia (Mizukami et al., 1997). We previously described that SB203580, a specific inhibitor of the p38 pathway, also partially protects cortical neurons against ceramide-induced apoptosis. Our results demonstrate that Dnc-Jun partially protects cortical neurons against ceramide-induced apoptosis. This is consistent with data obtained in others models, such as PC12 cells (Xia et al., 1995; Lambeng et al., 2003) and sympathetic neurons (Ham et al., 1995) deprived of NGF.

We previously described that SB203580, a specific inhibitor of the p38 pathway, also partially protects against ceramide-induced apoptosis (Willaime et al., 2001) in exactly the same conditions as in the present study. The cooperative role of p38 and JNK/c-Jun pathway remained to be addressed. Although the result was previously suggested in two articles, in each the specificity of pharmacological agents is contestable: Le Niculescu et al. used the p38 inhibitor SB202190 at high unspecific doses to also inhibit JNKs (Manthey et al., 1998; Le-Niculescu et al., 1999); Namgung and Xia used CEP1347 as a JNK inhibitor in cooperation with a p38 inhibitor (Namgung and Xia, 2000), but CEP1347 has since been shown to affect mixed lineage kinase family rather than directly JNKs (Maroney et al., 2001). In this study we have employed an alternative approach using p38 kinase inhibitor SB203580 and Dnc-Jun. We obtained a complete protection in our model. In others models, where Dnc-Jun alone almost completely protects cells against apoptosis, p38 kinase is not activated during apoptosis (Watson et al., 1998) or not described. Furthermore, Xia et al. showed that either Dnc-Jun...
Jun or dominant negative form of MKK3, upstream kinase of p38s, protects completely PC12 cells from NGF withdrawal-induced apoptosis. They did not explore the cooperative role of p38 and JNK/c-Jun pathway. Thus, our data further demonstrate that p38 kinase and JNK/c-Jun act in parallel to induce neuronal apoptosis by ceramide.

The pro-apoptotic action of p38 in ceramide-induced apoptosis may be mediated by apoptotic effectors: Bax translocation from the cytosol to the mitochondria is dependent upon p38 (Ghatal et al., 2000); Bid is cleaved upon p38 activation and leads to mitochondrial dysfunction (Zhuang et al., 2000); Fas-ligand expression is regulated by p38 and is pro-apoptotic (Zhang et al., 2000); GADD153/CHOP activation is controlled by p38 and is involved in ceramide-induced apoptosis (Brenner et al., 1997). The pro-apoptotic action of JNK/c-Jun in ceramide-induced apoptosis may be mediated by apoptotic effectors such as Fas-ligand which expression is also regulated by JNK (Herdegen et al., 1998; Morishima et al., 2001), since the Fas-ligand promoter contains an AP-1 site that enables the promoter to be activated by the JNK pathway. Bim, a pro-apoptotic member of Bcl-2 family, which is strongly induced in sympathetic neurons on NGF withdrawal, has also been shown to be under the transcriptional control of the JNK pathway (Putcha et al., 2001; Whitfield et al., 2001).

Our results show that p38 kinase and JNK/c-Jun act in parallel to induce neuronal apoptosis by ceramide. With this double inhibition, we obtained a complete protection against neuronal apoptosis. These results suggest that multitherapy with specific inhibitors of these signaling pathways could have important synergistic effects for inhibiting neuronal apoptosis.

Acknowledgements—We are grateful to C. Jarvis for critical review of the manuscript. We thank M. Yaniv for the DNC-Jun plasmid, T. Levade and S. Carpentier for the ceramide dosage. This work was partially supported by grants from Association France-Alzheimer (to S.W.M.), Association pour la Recherche sur la Parkinson (to J.M.).

REFERENCES

Lambeng N, Michel PP, Brugg B, Agid Y, Ruberg M (1999) Meca-
nisms of apoptosis in PC12 cells irreversibly differentiated with nerve growth factor and cyclic AMP. Brain Res 821:60–68.


(Accepted 11 December 2002)